Showing 1961-1970 of 2898 results for "".
- Allergan Reports Positive Phase 3 Data for New Short-acting Neurotoxinhttps://modernaesthetics.com/news/allergans-trenibotulinumtoxine-bonte-smoothes-glabellar-lines-quickly/2473513/Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. BoNT/E is a novel botulinum neurotoxin serotype E with a quick onset of action
- New Deadline: Allergan Aesthetics, University Lab Partners Launch Golden Passport Pitch Competition to Accelerate Aesthetics Start-Upshttps://modernaesthetics.com/news/news-you-can-use-allergan-aesthetics-university-lab-partners-launch-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups-1/2473512/University Lab Partners (ULP) and Allergan Aesthetics are launching the Golden Passport pitch competition for aesthetic startups. The Golden Passport provides the winner with a lab bench for one year and opportunities to engage with industry mentors including scientific and business lea
- Sentient Adds to C-Suitehttps://modernaesthetics.com/news/sentient-adds-to-c-suite/2473510/Brian Kirk is Sentient’s new Chief Marketing Officer (CMO), and Jennifer Redmond joins as Chief Revenue Officer (CRO). Mr. Kirk is charged with elevating Sentient's marketing investment to support Tixel by Sentient and Sentient Sculpt, wh
- Allergan Aesthetics, University Lab Partners Announce the Golden Passport Pitch Competition to Accelerate Aesthetics Start-Upshttps://modernaesthetics.com/news/allergan-aesthetics-university-lab-partners-announce-the-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups/2473509/University Lab Partners (ULP) is announcing the Golden Passport pitch competition for aesthetic startups sponsored by Allergan Aesthetics, an AbbVie Company. The Golden Passport provides the winner with a lab bench for one year and opportunities to engage with industry mentors including
- Hair Relaxers Linked to Uterine Cancer in Black Womenhttps://modernaesthetics.com/news/hair-relaxers-linked-to-uterine-cancer-in-black-women/2473506/Long-term use of chemical hair relaxers by postmenopausal Black women may increase risk of uterine cancer, according to a new study by researchers at Boston University’s Black Women’s Health Study (BWHS). These products contain potentially harmful ingredients, including chem
- BeautyHealth Launches New Hydrafacial School Partner Program for Student Estheticianshttps://modernaesthetics.com/news/beautyhealth-launches-new-hydrafacial-school-partner-program-for-student-estheticians/2473505/The Beauty Health Company is introducing the Hydrafacial School Partner Program to accredited esthetic schools across the U.S. Piloted first with select Paul Mitchell Schools and Aveda Institute locations, the Hydrafacial School Partner Program offers participating schools and the
- RelabotulinumtoxinA Update from Galdermahttps://modernaesthetics.com/news/relabotulinumtoxina-update-from-galderma/2473504/The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Galderma related to its pending Biologics License Application (BLA) for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity
- Industry Vet Aaron Green Joins RepeatMDhttps://modernaesthetics.com/news/industry-vet-aaron-green-joins-repeatmd/2473498/Aaron Green is RepeatMD’s new Vice President of Business Development. RepeatMD is a mobile shopping platform that integrates ecommerce and fintech solutions, providing aesthetic and wellness practices with a personalized shopping experience for their patients. &quo
- Will Platysma Prominence Be the Next Nod for BOTOX Cosmetic?https://modernaesthetics.com/news/will-platysma-prominence-be-the-next-nod-for-botox-cosmetic/2473497/Allergan Aesthetics’ BOTOX Cosmetic met all primary and secondary endpoints for the treatment of moderate to severe platysma prominence associated with platysma muscle activity, according to topline results from the second of three Phase 3 studies. The multicenter, randomized
- FDA Grants 510(k) Clearance to Venus the Versa Pro Systemhttps://modernaesthetics.com/news/fda-grants-510k-clearance-to-venus-the-versa-pro-system/2473495/The U.S. Food and Drug Administration has granted marketing clearance to Venus Concept Inc.’s Venus Versa Pro System. Venus Versa is customizable and upgradable and supports 10 optional applicators which utilize Venus Concept’s (MP)2, IPL and NanoFractional RF tec